​

Humana (HUM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

HUM Stock Forecast

Humana stock forecast is as follows: an average price target of $292.13 (represents a 23.90% upside from HUM’s last price of $235.78) and a rating consensus of 'Hold', based on 25 wall street analysts offering a 1-year stock forecast.

HUM Price Target

The average price target for Humana (HUM) is $292.13 based on 1-year price targets from 25 Wall Street analysts in the past 3 months, with a price target range of $400.00 to $247.00. This represents a potential 23.90% upside from HUM's last price of $235.78.

HUM Analyst Ratings

Hold

According to 25 Wall Street analysts, Humana's rating consensus is 'Hold'. The analyst rating breakdown for HUM stock is 0 'Strong Buy' (0.00%), 8 'Buy' (32.00%), 16 'Hold' (64.00%), 1 'Sell' (4.00%), and 0 'Strong Sell' (0.00%).

Humana Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 04, 2024George HillDeutsche Bank$248.00$287.64-13.78%5.18%
Oct 22, 2024George HillDeutsche Bank$250.00$260.57-4.06%6.03%
Oct 10, 2024Andrew MokBarclays$250.00$245.451.85%6.03%
Oct 08, 2024Ben HendrixRBC Capital$265.00$236.2912.15%12.39%
Oct 07, 2024David WindleyJefferies$253.00$240.035.40%7.30%
Oct 03, 2024Jessica TassanPiper Sandler$274.00$239.3214.49%16.21%
Oct 02, 2024Kevin FischbeckBank of America Securities$247.00$246.490.21%4.76%
Sep 27, 2024David WindleyJefferies$419.00$319.5731.11%77.71%
Sep 05, 2024Frank MorganRBC Capital$400.00$364.069.87%69.65%
Aug 01, 2024Michael WiederhornOppenheimer$400.00$361.6110.62%69.65%
Jul 15, 2024David MacDonaldTruist Financial$400.00$382.224.65%69.65%
Jun 25, 2024Jessica TassanPiper Sandler$392.00$355.8010.17%66.26%
Jun 20, 2024Andrew MokBarclays$370.00$349.555.85%56.93%
Apr 25, 2024Michael WiederhornOppenheimer$370.00$315.9817.10%56.93%
Apr 25, 2024Frank MorganRBC Capital$353.00$315.9811.72%49.72%
Apr 25, 2024Sarah JamesCantor Fitzgerald$360.00$315.9813.93%52.68%
Apr 02, 2024Andrew MokBarclays$310.00$351.45-11.79%31.48%
Feb 07, 2023Truist Financial$560.00$474.1018.12%137.51%
Feb 06, 2023Cowen & Co.$581.00$484.7119.87%146.42%
Feb 06, 2023Credit Suisse$575.00$476.5720.65%143.87%
Feb 02, 2023UBS$620.00$486.0227.57%162.96%
Jan 06, 2023J.P. Morgan$625.00$492.5426.89%165.08%
Dec 13, 2022Nathan RichGoldman Sachs$652.00$528.8923.28%176.53%
Nov 10, 2022Mizuho Securities$615.00$558.3010.16%160.84%
Sep 20, 2022RBC Capital$544.00$505.887.54%130.72%
Sep 16, 2022Truist Financial$570.00$493.3815.53%141.75%
Sep 16, 2022Oppenheimer$550.00$491.4911.90%133.27%
Aug 02, 2022Morgan Stanley$494.00$474.444.12%109.52%
Jul 28, 2022Barclays$570.00$478.3519.16%141.75%
Jul 28, 2022Mizuho Securities$529.00$478.3510.59%124.36%
Jul 28, 2022Oppenheimer$520.00$478.358.71%120.54%
Jul 28, 2022Leerink Partners$540.00$478.3512.89%129.03%
Jul 26, 2022David MacDonaldTruist Financial$550.00$491.7911.84%133.27%
May 25, 2022Wells Fargo$514.00$443.0016.03%118.00%
Apr 28, 2022Wells Fargo$512.00$457.3111.96%117.15%
Apr 28, 2022RBC Capital$541.00$442.3022.32%129.45%
Apr 28, 2022Leerink Partners$535.00$443.3720.67%126.91%
Apr 19, 2022Kevin CaliendoUBS$520.00$453.9714.55%120.54%
Apr 11, 2022David MacDonaldTruist Financial$490.00$451.338.57%107.82%
Jan 07, 2022Kevin CaliendoUBS$486.00$362.5234.06%106.12%
Jan 07, 2022Steven ValiquetteBarclays$490.00$362.5235.16%107.82%
Dec 14, 2021Nathan RichGoldman Sachs$472.00$460.342.53%100.19%
Nov 04, 2021Michael WiederhornOppenheimer$510.00$452.0612.82%116.30%
Nov 04, 2021Kevin FischbeckBank of America Securities$530.00$452.0617.24%124.79%
Nov 04, 2021A.J. RiceCredit Suisse$513.00$452.0613.48%117.58%
Nov 03, 2021Steven HalperCantor Fitzgerald$480.00$457.944.82%103.58%
Sep 09, 2021Gary TaylorCowen & Co.$479.00$415.0115.42%103.16%
Aug 04, 2021Michael NewshelEvercore ISI$450.00$424.066.12%90.86%
Aug 03, 2021Scott FidelStephens$500.00$423.3418.11%112.06%
Jul 09, 2021Lisa GillJ.P. Morgan$514.00$453.3513.38%118.00%
Apr 26, 2021Justin LakeWolfe Research$498.00$443.1912.37%111.21%

The latest Humana stock forecast, released on Dec 04, 2024 by George Hill from Deutsche Bank, set a price target of $248.00, which represents a -13.78% decrease from the stock price at the time of the forecast ($287.64), and a 5.18% increase from HUM last price ($235.78).

Humana Price Target by Period

1M3M12M
# Anlaysts1817
Avg Price Target$248.00$275.75$327.12
Last Closing Price$235.78$235.78$235.78
Upside/Downside5.18%16.95%38.74%

In the current month, the average price target of Humana stock is $248.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 5.18% increase as opposed to Humana's last price of $235.78. This month's average price target is down -10.06% compared to last quarter, and down -24.19% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Dec 04, 2024Deutsche BankHoldHoldHold
Nov 06, 2024Bank of America SecuritiesNeutralNeutralUpgrade
Oct 22, 2024Deutsche BankHoldHoldHold
Oct 11, 2024OppenheimerOutperformOutperformHold
Oct 10, 2024KeyBancSector WeightInitialise
Oct 10, 2024BarclaysEqual-WeightEqual-WeightHold
Oct 08, 2024RBC CapitalOutperformOutperformHold
Oct 08, 2024BernsteinMarket PerformOutperformUpgrade
Oct 07, 2024Zacks Investment ResearchNegativeDowngrade
Oct 07, 2024Cowen & Co.BuyHoldDowngrade
Oct 07, 2024JefferiesBuyHoldDowngrade
Oct 03, 2024Piper SandlerUnderperformNeutralDowngrade
Oct 02, 2024StephensOverweightEqual-WeightDowngrade
Oct 01, 2024RBC CapitalBuyBuyHold
Sep 27, 2024JefferiesBuyBuyHold
Sep 05, 2024RBC CapitalBuyBuyHold
Sep 05, 2024Raymond JamesUnderperformUnderperformHold
Sep 05, 2024RBC CapitalOutperformOutperformHold
Aug 19, 2024Piper SandlerUnderperformUnderperformHold
Aug 01, 2024Raymond JamesBuyBuyHold
Aug 01, 2024OppenheimerOutperformOutperformHold
Jul 15, 2024UBSBuyBuyHold
Jun 24, 2024Morgan StanleyOverweightEqual-WeightInitialise
Jun 20, 2024BarclaysEqual-WeightEqual-WeightHold
Jun 12, 2024Wells FargoBuyBuyHold
May 20, 2024UBSUnderperformUnderperformHold
May 20, 2024Wells FargoBuyBuyHold
Apr 25, 2024UBSUnderperformUnderperformHold
Apr 25, 2024OppenheimerOutperformOutperformHold
Apr 25, 2024RBC CapitalOutperformOutperformHold
Apr 25, 2024Cantor FitzgeraldNeutralNeutralHold
Apr 08, 2024Wells FargoBuyBuyHold
Apr 08, 2024BarclaysOutperformOutperformHold
Apr 02, 2024Bank of America SecuritiesNeutralDowngrade
Apr 02, 2024Cowen & Co.BuyBuyHold
Mar 06, 2024UBSUnderperformUnderperformHold
Mar 06, 2024Wells FargoBuyBuyHold
Jan 26, 2024StephensOverweightOverweightHold
Jan 26, 2024Goldman SachsBuyBuyHold
Jan 26, 2024RBC CapitalOutperformOutperformHold
Jan 17, 2024StephensBuyBuyHold
Aug 03, 2023StephensOverweightOverweightHold
Apr 21, 2023Cantor FitzgeraldNeutralInitialise
Feb 06, 2023Cowen & Co.OutperformOutperformHold
Feb 06, 2023Credit SuisseOutperformOutperformHold
Feb 03, 2023StephensOverweightOverweightHold
Feb 02, 2023UBSBuyBuyHold
Dec 13, 2022Piper SandlerOverweightUpgrade
Dec 13, 2022National BankMarket PerformDowngrade
Dec 13, 2022Keefe, Bruyette & WoodsMarket PerformDowngrade
Dec 13, 2022Raymond JamesMarket PerformDowngrade
Dec 13, 2022Goldman SachsBuySellDowngrade
Dec 13, 2022CitigroupNeutralUpgrade
Dec 13, 2022Goldman SachsBuyUpgrade
Nov 03, 2022SVB LeerinkOutperformOutperformHold
Oct 26, 2022Deutsche BankBuyUpgrade
Sep 20, 2022BenchmarkHoldInitialise
Sep 20, 2022RBC CapitalOutperformOutperformHold
Sep 20, 2022Morgan StanleyEqual-WeightOverweightUpgrade
Sep 16, 2022OppenheimerOutperformOutperformHold
Aug 02, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Jul 28, 2022BarclaysOverweightOverweightHold
Jul 28, 2022OppenheimerOutperformOutperformHold
Jul 28, 2022SVB LeerinkOutperformOutperformHold
May 25, 2022Wells FargoOverweightOverweightHold
Apr 28, 2022Wells FargoOverweightOverweightHold
Apr 28, 2022RBC CapitalOutperformOutperformHold
Apr 28, 2022SVB LeerinkOutperformOutperformHold
Apr 26, 2022Canaccord GenuityHoldHoldHold
Apr 19, 2022UBSBuyUpgrade
Jan 14, 2022BernsteinMarket PerformMarket PerformHold
Jan 10, 2022BMO CapitalMarket PerformMarket PerformHold

Humana's last stock rating was published by Deutsche Bank on Dec 04, 2024. The company gave HUM a "Hold" rating, the same as its previous rate.

Humana Financial Forecast

Humana Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$26.42B$26.75B$26.74B$22.44B$22.80B$23.66B$23.97B$21.05B$20.70B$20.64B$20.67B$19.06B$20.07B$19.08B$18.93B$16.30B$16.24B
Avg Forecast$29.27B$29.89B$30.31B$30.61B$29.31B$29.83B$30.20B$30.67B$28.72B$28.68B$28.52B$28.52B$25.51B$25.57B$25.83B$26.43B$22.48B$22.82B$23.45B$23.54B$21.22B$20.90B$20.51B$20.48B$18.77B$18.62B$18.64B$18.45B$16.19B$16.15B
High Forecast$30.48B$31.12B$31.56B$31.87B$30.52B$31.06B$31.45B$32.17B$29.08B$28.74B$28.52B$28.52B$25.86B$26.79B$26.89B$27.52B$23.41B$22.82B$23.45B$23.54B$21.22B$20.90B$20.51B$20.48B$18.77B$18.62B$18.64B$18.45B$16.19B$16.15B
Low Forecast$28.28B$28.88B$29.29B$29.58B$28.33B$28.83B$29.18B$29.91B$28.25B$28.62B$28.52B$28.52B$25.32B$24.74B$24.96B$25.54B$21.72B$22.82B$23.45B$23.54B$21.22B$20.90B$20.51B$20.48B$18.77B$18.62B$18.64B$18.45B$16.19B$16.15B
# Analysts644643791154451599131313137777987655
Surprise %-------------1.03%1.04%1.01%1.00%1.00%1.01%1.02%0.99%0.99%1.01%1.01%1.02%1.08%1.02%1.03%1.01%1.01%

Humana's average Quarter revenue forecast for Dec 23 based on 5 analysts is $25.51B, with a low forecast of $25.32B, and a high forecast of $25.86B. HUM's average Quarter revenue forecast represents a -3.44% decrease compared to the company's last Quarter revenue of $26.42B (Sep 23).

Humana EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts644643791154451599131313137777987655
EBITDA-------------$1.40B$1.57B$1.90B$252.00M$1.62B$1.43B$1.51B$220.00M$1.92B$1.02B$1.30B$-220.00M$2.03B$2.84B$930.00M$789.00M$1.11B
Avg Forecast$1.66B$1.70B$1.72B$1.74B$1.66B$1.69B$1.71B$1.74B$1.63B$1.63B$1.62B$1.71B$1.45B$1.45B$1.47B$1.56B$223.06M$1.31B$1.34B$1.23B$1.22B$1.20B$1.17B$1.18B$1.08B$1.07B$1.07B$786.92M$927.50M$925.48M
High Forecast$1.73B$1.77B$1.79B$1.81B$1.73B$1.76B$1.78B$1.83B$1.65B$1.63B$1.62B$2.05B$1.47B$1.52B$1.53B$1.87B$267.67M$1.31B$1.34B$1.48B$1.22B$1.20B$1.17B$1.42B$1.08B$1.07B$1.07B$944.31M$927.50M$925.48M
Low Forecast$1.61B$1.64B$1.66B$1.68B$1.61B$1.64B$1.66B$1.70B$1.60B$1.62B$1.62B$1.37B$1.44B$1.40B$1.42B$1.24B$178.45M$1.31B$1.34B$984.16M$1.22B$1.20B$1.17B$947.95M$1.08B$1.07B$1.07B$629.54M$927.50M$925.48M
Surprise %-------------0.97%1.07%1.22%1.13%1.24%1.07%1.23%0.18%1.60%0.87%1.09%-0.20%1.90%2.66%1.18%0.85%1.20%

5 analysts predict HUM's average Quarter EBITDA for Dec 23 to be $1.45B, with a high of $1.47B and a low of $1.44B. This is 3.22% upper than Humana's previous annual EBITDA (Sep 23) of $1.40B.

Humana Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts644643791154451599131313137777987655
Net Income-------------$832.00M$959.00M$1.24B$-13.00M$1.20B$696.00M$930.00M$-9.00M$1.53B$588.00M$828.00M$-280.00M$1.34B$1.83B$473.00M$512.00M$689.00M
Avg Forecast$-182.49M$384.86M$675.29M$706.15M$-141.96M$508.84M$830.17M$852.11M$-251.20M$412.88M$708.16M$1.05B$97.49M$865.00M$1.06B$957.82M$-14.19M$757.34M$925.05M$757.17M$139.63M$564.13M$823.57M$756.46M$-285.83M$339.37M$1.24B$400.23M$264.96M$552.05M
High Forecast$-174.51M$405.51M$711.53M$744.05M$-135.75M$536.14M$874.72M$982.66M$-168.63M$417.12M$708.17M$1.26B$118.38M$909.70M$1.11B$1.15B$-11.36M$757.34M$925.05M$908.60M$139.63M$564.13M$823.57M$907.75M$-285.83M$339.37M$1.24B$480.28M$264.96M$552.05M
Low Forecast$-192.29M$368.03M$645.76M$675.27M$-149.58M$486.58M$793.86M$755.98M$-293.07M$408.65M$708.16M$842.88M$-6.43M$851.71M$1.01B$766.25M$-17.03M$757.34M$925.05M$605.73M$139.63M$564.13M$823.57M$605.17M$-285.83M$339.37M$1.24B$320.18M$264.96M$552.05M
Surprise %-------------0.96%0.91%1.29%0.92%1.58%0.75%1.23%-0.06%2.71%0.71%1.09%0.98%3.95%1.47%1.18%1.93%1.25%

Humana's average Quarter net income forecast for Dec 23 is $97.49M, with a range of $-6.43M to $118.38M. HUM's average Quarter net income forecast represents a -88.28% decrease compared to the company's last Quarter net income of $832.00M (Sep 23).

Humana SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts644643791154451599131313137777987655
SG&A--------------------$3.40B$2.60B$2.12B$2.01B$3.07B$2.51B$2.35B$2.12B$2.13B$1.89B
Avg Forecast$2.91B$2.97B$3.01B$3.04B$2.92B$2.97B$3.00B$3.05B$2.86B$2.85B$2.84B$2.84B$2.54B$2.54B$2.57B$2.63B$3.44B$2.81B$2.89B$2.90B$2.61B$2.58B$2.53B$1.83B$2.31B$2.29B$2.30B$1.79B$1.99B$1.99B
High Forecast$3.03B$3.09B$3.14B$3.17B$3.04B$3.09B$3.13B$3.20B$2.89B$2.86B$2.84B$2.84B$2.57B$2.66B$2.67B$2.74B$4.13B$2.81B$2.89B$2.90B$2.61B$2.58B$2.53B$2.20B$2.31B$2.29B$2.30B$2.15B$1.99B$1.99B
Low Forecast$2.81B$2.87B$2.91B$2.94B$2.82B$2.87B$2.90B$2.97B$2.81B$2.85B$2.84B$2.84B$2.52B$2.46B$2.48B$2.54B$2.75B$2.81B$2.89B$2.90B$2.61B$2.58B$2.53B$1.47B$2.31B$2.29B$2.30B$1.43B$1.99B$1.99B
Surprise %--------------------1.30%1.01%0.84%1.09%1.33%1.10%1.03%1.18%1.07%0.95%

Humana's average Quarter SG&A projection for Mar 22 is $2.90B, based on 13 Wall Street analysts, with a range of $2.90B to $2.90B. The forecast indicates a -14.60% fall compared to HUM last annual SG&A of $3.40B (Dec 21).

Humana EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts644643791154451599131313137777987655
EPS-------------$6.74$7.70$9.91$-0.10$9.45$5.50$7.32$-0.07$11.91$4.57$6.42$-2.12$10.12$13.83$3.58$3.87$5.16
Avg Forecast$-1.51$3.19$5.59$5.85$-1.18$4.21$6.87$7.06$-2.08$3.42$5.86$6.12$0.81$7.16$8.76$9.27$1.46$6.28$7.67$6.80$1.16$4.68$6.83$7.07$-2.37$2.81$10.27$4.66$2.20$4.58
High Forecast$-1.45$3.36$5.89$6.16$-1.12$4.44$7.24$8.14$-1.40$3.45$5.86$6.12$0.98$7.53$9.23$9.77$1.54$6.28$7.67$6.80$1.16$4.68$6.83$7.07$-2.37$2.81$10.27$4.66$2.20$4.58
Low Forecast$-1.59$3.05$5.35$5.59$-1.24$4.03$6.57$6.26$-2.43$3.38$5.86$6.12$-0.05$7.05$8.37$8.86$1.40$6.28$7.67$6.80$1.16$4.68$6.83$7.07$-2.37$2.81$10.27$4.66$2.20$4.58
Surprise %-------------0.94%0.88%1.07%-0.07%1.51%0.72%1.08%-0.06%2.55%0.67%0.91%0.89%3.60%1.35%0.77%1.76%1.13%

According to 5 Wall Street analysts, Humana's projected average Quarter EPS for Dec 23 is $0.81, with a low estimate of $-0.05 and a high estimate of $0.98. This represents a -88.02% decrease compared to HUM previous annual EPS of $6.74 (Sep 23).

Humana Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
CVSCVS Health$44.04$73.5066.89%Buy
CICigna$265.59$400.0050.61%Buy
ELVElevance Health$366.30$542.1448.00%Buy
CNCCentene$57.81$81.5040.98%Buy
UNHUnitedHealth Group$485.52$618.7527.44%Buy
HUMHumana$233.89$292.1324.90%Hold
MOHMolina Healthcare$291.78$347.0018.93%Hold
ALHCAlignment Healthcare$10.83$10.00-7.66%Buy

HUM Forecast FAQ

Is Humana a good buy?

No, according to 25 Wall Street analysts, Humana (HUM) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 32.00% of HUM's total ratings.

What is HUM's price target?

Humana (HUM) average price target is $292.13 with a range of $247 to $400, implying a 23.90% from its last price of $235.78. The data is based on 25 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Humana stock go up soon?

According to Wall Street analysts' prediction for HUM stock, the company can go up by 23.90% (from the last price of $235.78 to the average price target of $292.13), up by 69.65% based on the highest stock price target, and up by 4.76% based on the lowest stock price target.

Can Humana stock reach $400?

HUM's average twelve months analyst stock price target of $292.13 does not support the claim that Humana can reach $400 in the near future.

What is Humana's current price target trend?

1 Wall Street analyst forecast a $248 price target for Humana (HUM) this month, up 5.18% from its last price of $235.78. Compared to the last 3 and 12 months, the average price target increased by 16.95% and increased by 38.74%, respectively.

What are Humana's analysts' financial forecasts?

Humana's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $120.02B (high $125.21B, low $116.25B), average EBITDA is $6.81B (high $7.11B, low $6.6B), average net income is $2.05B (high $2.26B, low $1.89B), average SG&A $11.93B (high $12.45B, low $11.56B), and average EPS is $16.97 (high $18.7, low $15.62). HUM's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $120.07B (high $125.03B, low $116.03B), average EBITDA is $6.82B (high $7.1B, low $6.59B), average net income is $1.58B (high $1.69B, low $1.5B), average SG&A $11.94B (high $12.43B, low $11.54B), and average EPS is $13.11 (high $13.97, low $12.39).

Did the HUM's actual financial results beat the analysts' financial forecasts?

Based on Humana's last annual report (Dec 2022), the company's revenue was $92.87B, beating the average analysts forecast of $92.28B by 0.64%. Apple's EBITDA was $4.81B, beating the average prediction of $4.1B by 17.31%. The company's net income was $2.81B, beating the average estimation of $2.43B by 15.69%. Apple's SG&A was $0, missing the average forecast of $12.04B by -100.00%. Lastly, the company's EPS was $21.8, missing the average prediction of $22.2 by -1.82%. In terms of the last quarterly report (Sep 2023), Humana's revenue was $26.42B, beating the average analysts' forecast of $25.57B by 3.33%. The company's EBITDA was $1.4B, missing the average prediction of $1.45B by -3.35%. Humana's net income was $832M, missing the average estimation of $865M by -3.82%. The company's SG&A was $0, missing the average forecast of $2.54B by -100.00%. Lastly, the company's EPS was $6.74, missing the average prediction of $7.16 by -5.90%